| |
ER+
|
MBC
|
DBC
|
BRCA1
|
|---|
| |
Luminal B
|
Luminal A
|
Normal
|
Basal
|
HER2
| | | |
|---|
|
n
|
97
|
337
|
32
|
19
|
42
|
22
|
44
|
18
|
|
n classifiable
|
37
|
113
|
19
|
17
|
16
|
20
|
33
|
16
|
|
CC+/IR+
|
17
|
2
|
0
|
13
|
11
|
14
|
4
|
13
|
|
CC+
|
20
|
2
|
0
|
4
|
1
|
3
|
3
|
2
|
|
ECM+
|
0
|
71
|
16
|
0
|
0
|
1
|
3
|
1
|
|
SR+
|
0
|
9
|
0
|
0
|
0
|
0
|
20
|
0
|
|
IR+
|
0
|
29
|
3
|
0
|
4
|
2
|
3
|
0
|
- Classification of ER+ intrinsic subtypes (527 samples from the integrated cohort NKI2 + EMC + NCH), 22 medullary breast cancers (MBCs) and 44 ductal breast cancers (DBCs) from [38], and 18 BRCA1 mutants from [3] into ER- subclasses, using the nearest centroid criterion with Pearson correlation as distance metric. Only samples with Pearson correlation coefficients larger than 0.25 were deemed classifiable. ER, estrogen receptor.
